Table 1 Baseline demographic and clinicopathological characteristics by randomized treatment groups.
Characteristic | Placebo | Vitamin D + Placebo | Synbiotics + Placebo | Vitamin D + Synbiotics | Significance |
|---|---|---|---|---|---|
Group A (n = 22) | Group B (n = 15) | Group C (n = 21) | Group D (n = 18) | ||
Age, years (mean) | 50 | 49.6 | 46.5 | 46.7 | 0.61 |
Weight (kilogram) | 72.4 | 72.7 | 71 | 72.8 | 0.92 |
BMI (kg/m2) | 28.2 | 28.3 | 28.9 | 29.1 | 0.58 |
Tumor grade | |||||
Low | 3 (13.6) | 2 (13.3) | 3 (14.3) | 0 | 0.251 |
Intermediate | 16 (72.2) | 6 (40.0) | 11 (52.4) | 12 (66.6) | |
High | 3 (13.6) | 6 (40.0) | 7 (33.3) | 5 (27.7) | |
Not known | 0 | 1 (6.6) | 0 | 1 (5.5) | |
Histologic Type | |||||
Ductal | 20 (90.9) | 14 (93.3) | 19 (90.5) | 18 (100) | 0.709 |
Lobular | 2 (9.1) | 1 (6.6) | 2 (9.5) | 0 | |
ER status | |||||
Positive | 16 (72.7) | 9 (60) | 11 (52.4) | 11 (61.1) | 0.701 |
Negative | 6 (27.3) | 5 (33.3) | 9 (42.8) | 7 (38.9) | |
PR status | |||||
Positive | 13 (59.1) | 7 (46.6) | 9 (42.8) | 9 (50) | 0.842 |
Negative | 9 (40.9) | 7 (46.6) | 11 (52.4) | 9 (50) | |
Not known | 0 | 1 (6.6) | 1 (4.7) | 0 | |
HER2 status | |||||
0 | 13 (59.1) | 7 (50) | 11 (55) | 9 (50) | 0.933 |
1 | 1 (4.5) | 1 (7.1) | 3 (15) | 2 (11.1) | |
2 | 2 (9.1) | 1 (7.1) | 0 | 2 (11.1) | |
3 | 6 (27.3) | 5 (35.8) | 6 (30) | 5 (27.8) | |
